Brazilian Medical Device Manufacturers (2026)

Brazil’s medical device manufacturers exported $1.17 billion in 2024, a 24.6% increase over the prior year, reaching buyers in 131 countries. The sector is represented by ABIMO, with more than 330 member companies producing everything from heart valves to orthopedic implants. Yet most of these manufacturers still rely on trade fairs, distributors, and government-backed trade missions to find international buyers.

The Numbers Behind Brazil’s Medical Device Sector

The growth is not slowing down. According to DatamarNews reporting on ABIMO data, Brazilian medical device exports hit $1.17 billion in 2024, building on the $1.06 billion milestone in 2023 (which itself was a 13.69% jump).

The breakdown by segment tells you where the strength sits:

Segment	2024 Exports	YoY Growth
Medical-hospital products	$804.89 million	+32%
Dental products	$135.97 million	+11.7%
Laboratory products	$123.93 million	+15.1%
Rehabilitation products	$109.48 million	+7.01%

Medical-hospital products alone account for 68.54% of total exports. That category grew 32% in a single year. In Q1 2025, ABIMO reported exports of $247.6 million, a further 22.3% increase year-over-year, so the momentum has not slowed.

Brazil’s overall medical technology market is projected to reach US$12.97 billion in 2025, with medical devices accounting for $11.12 billion of that total. The country operates 7,309 hospitals with over 500,000 beds, creating a massive domestic demand base alongside the growing export engine.

Where Brazilian Medical Devices Go

The export destinations reveal both opportunity and concentration risk. According to ABIMO data reported by DatamarNews:

Top five destinations: United States, Argentina, Mexico, Chile, and Colombia.

Regional breakdown:

• Americas: 63.1%
• Europe: 20.86%
• Asia: 14.25%
• Africa and Oceania: 1.78%

South Korea and the Netherlands also emerged as significant buyers. The Americas’ 63.1% share means nearly two-thirds of all medical device exports stay in the Western Hemisphere. European and Asian markets, where healthcare budgets are large and growing, remain underpenetrated.

The import side makes the case even stronger. Brazil imported $9.79 billion in medical devices in 2024, a 20.49% increase, primarily from the United States, Germany, China, Ireland, and Switzerland. That $8.6 billion trade deficit signals that international buyers already trust the category. Brazilian manufacturers simply have not built enough direct relationships outside their traditional markets.

What Brazilian Manufacturers Actually Produce

The top exported product categories show what this sector actually makes:

• Heart valves and cardiovascular devices
• Orthopedic articles and devices (implants, fixation systems, prosthetics)
• Dental instruments and filling materials
• Sterilized catgut sutures and wound closure products
• Liquid distribution and dosing equipment for hospital use
• Medical plastic bags and pouches for sterile applications

None of these are commodity items. Heart valves require ISO 13485-certified cleanrooms. Orthopedic implants go through years of clinical validation. Brazilian companies have built that manufacturing capability over decades. What many still lack is a repeatable way to get in front of procurement teams at hospitals and distributors outside Latin America.

A few names illustrate the range. Braile Biomedica in Sao Jose do Rio Preto has manufactured cardiac surgery devices, including heart valves and oxygenators, since 1977. Baumer produces orthopedic implants and surgical instruments from its base in Mogi Mirim, supplying hospitals across Latin America and beyond. Gnatus in Ribeirao Preto is one of the largest dental equipment manufacturers in the Southern Hemisphere. These are established companies with real production capacity, not startups chasing trends.

The Brazilian Health Devices (BHD) program, run by ABIMO in partnership with ApexBrasil, supports 125 exporting companies. In 2024, BHD participants exported $154.5 million across 210 device types. More than 81% of participating companies increased their export volume, and 84 companies expanded into new markets.

Jose Fernando Dantas, Market Access Coordinator at ABIMO, stated: “The positive performance shows that the Brazilian Health Devices project continues to be efficient in its goal of promoting the Brazil brand in the international medical device market.”

The Regulatory Foundation: ANVISA and Global Compliance

Brazilian medical device manufacturers operate under ANVISA’s RDC 751/2022, which established a risk-based classification system aligned with international standards. Devices are classified into four risk categories (Class I through Class IV), with registration timelines ranging from 30 days for low-risk devices to 9-20 months for high-risk products.

New Unique Device Identifier (UDI) requirements are rolling out in phases: Class IV devices from July 2025, Class III from January 2026, Class II from 2027, and Class I from 2028. Brazil also participates in the Medical Device Single Audit Program (MDSAP) alongside the United States, Canada, Japan, and Australia.

This regulatory alignment matters for exports. A manufacturer already complying with ANVISA’s updated framework has a shorter path to CE marking, FDA clearance, or approval in other MDSAP member countries. It is a competitive advantage that many Brazilian companies underestimate in their export sales conversations.

Why Conventional Sales Channels Are Falling Short

Brazilian medical device manufacturers have relied on a predictable set of channels for international sales. Every one of them has limits that become more visible as the sector scales.

Trade Fairs: High Cost, Narrow Windows

HOSPITALAR in Sao Paulo is Latin America’s largest healthcare trade fair. The 2025 edition brought together 1,200 exhibitors from 50 countries and over 80,000 visitors across four days. For a mid-size Brazilian manufacturer, exhibiting there costs $15,000 to $40,000 when you add booth space, design, staffing, and travel.

MEDICA in Dusseldorf is the global benchmark. With 5,000+ exhibitors from 165 countries and 80,000 visitors, it is the single most important trade fair for medical device companies targeting Europe. A competitive booth presence runs $30,000 to $70,000, plus international flights and accommodation for a week.

Arab Health in Dubai (now rebranded as World Health Expo) draws over 4,250 exhibitors and 106,000+ attendees. Middle Eastern healthcare spending is growing fast, but booth costs, logistics, and visa requirements make this a $25,000 to $50,000 commitment for a Brazilian supplier.

Each fair gives you three to five days of visibility. Then silence for 360 days. At $300 to $900+ per qualified lead, the ROI gets thinner every year. And procurement decisions do not pause between fairs.

Field Sales Representatives: Expensive and Geographically Locked

A medical device sales representative in Brazil earns an average of BRL 94,380 per year (roughly $18,000 to $19,000). That is the base cost. Add international travel, benefits, CRM tools, and management overhead for export-focused reps, and you reach $35,000 to $55,000 per person per year.

One rep covers one or two markets. Reaching hospital procurement directors in Germany, distributors in the Gulf states, and group purchasing organizations in the US requires separate hires for each region. At $500 to $1,200+ per qualified lead, field sales is the most expensive channel, and it scales linearly. Double the markets, double the cost.

The language and regulatory complexity compounds the problem. Selling medical devices to a procurement team in Dusseldorf requires German fluency, knowledge of EU MDR requirements, and familiarity with hospital group purchasing structures. Building that capability from Sao Paulo takes years.

Distributor Lock-In and Margin Erosion

Many mid-size Brazilian manufacturers export through distributors and trading houses that handle logistics, regulatory filing in the destination market, and buyer relationships. These intermediaries take 20-35% margins, and they own the customer relationship. The manufacturer rarely knows who the end buyer is.

When a distributor finds a cheaper alternative from China or India, the Brazilian supplier loses the account with no warning and no recourse. The distributor relationship that once enabled market entry becomes the ceiling on growth.

Government Trade Missions: Helpful, Not Scalable

Programs like Brazilian Health Devices and ApexBrasil trade missions play an important role in initial market exposure. But they run on fixed calendars, serve dozens of companies simultaneously, and cannot replace a continuous sales pipeline. A trade mission to the Middle East once a year does not build the kind of consistent presence that wins long-term hospital supply contracts.

Building Direct Buyer Pipelines With AI Outbound

An AI-powered outbound engine solves the structural problem: it lets Brazilian medical device manufacturers reach procurement teams across multiple countries simultaneously, without the cost structure of field sales or the calendar dependency of trade fairs.

How It Works in Practice

The system identifies buying signals across target markets: hospital expansion announcements, new regulatory approvals creating demand, group purchasing organization RFP postings, procurement team hires, and distributor network changes. When a German hospital group posts a tender for orthopedic implant suppliers, your company can be in their procurement inbox that week.

Messages are built around each prospect’s specific context: the devices they currently source, the regulatory standards they require, the clinical specialties they serve, and why your products and certifications align. This runs in English, German, Spanish, Arabic, and Portuguese simultaneously, reaching buyers across five or more markets without hiring native-speaking sales teams for each.

Here is what the numbers look like side by side:

Channel	Cost per Qualified Lead	Scale Pattern
AI outbound	$150-$300	Gets cheaper over time as targeting improves
Trade fairs	$300-$900+	Scales linearly with each event
Field sales reps	$500-$1,200+	Scales worse than linearly with each hire
Distributors	20-35% margin erosion	No direct buyer relationships

The difference shows up after month six. Trade fairs reset to zero every cycle. Field reps hit coverage ceilings. AI outbound gets better with time: every campaign refines targeting, sharpens messaging, and adds to a growing database of engaged prospects. Reaching the second 1,000 prospects costs less than the first 1,000.

See exactly how the pipeline works step by step.

What the First 90 Days Look Like

The first month is about defining who you want to sell to. Which European hospital groups, Middle Eastern distributors, and North American GPOs actually buy the devices you manufacture? What certifications do they require (CE marking, FDA 510(k), MDSAP)? What buying signals indicate active procurement? This becomes the foundation for targeting and messaging.

In month two, outreach launches to the first wave of prospects across two or three markets beyond Latin America. You monitor response rates, learn which messages land with hospital procurement teams versus distributor sourcing managers, and adjust based on real engagement data. First positive replies typically arrive here.

By month three, campaigns expand to additional regions and buyer segments. New buying signals get layered in, such as regulatory changes creating demand or competitor supply chain disruptions. Warm leads move through follow-up sequences. By day 90, you should have active conversations with procurement teams who had never heard of your company 90 days earlier.

This does not replace HOSPITALAR or your existing distributor relationships. It fills the 360+ days per year when you are not at an event and your sales team cannot be in every market at once.

Frequently Asked Questions

How large is Brazil’s medical device export market?

Brazilian manufacturers exported $1.17 billion in medical devices in 2024, a 24.6% increase over 2023, per ABIMO data. Medical-hospital products led with $804.89 million (68.54% of exports). Q1 2025 showed further 22.3% growth, reaching $247.6 million. Exports reached 131 countries, with the US, Argentina, and Mexico as top destinations.

What types of medical devices does Brazil export?

The main categories are heart valves, orthopedic devices and implants, dental instruments, sterilized sutures, dosing equipment, and medical plastic bags. BHD participants exported 210 distinct device types in 2024. The sector ranges from high-complexity cardiovascular devices to precision dental equipment and rehabilitation products.

What regulatory certifications do Brazilian medical device exporters hold?

Most export-ready Brazilian manufacturers comply with ANVISA RDC 751/2022, which aligns with international risk-based classification standards. Brazil participates in MDSAP alongside the US, Canada, Japan, and Australia. Many exporters also hold ISO 13485 certification. This regulatory foundation shortens the path to CE marking and FDA clearance for companies expanding into new markets.

How much does it cost to exhibit at a medical device trade fair?

HOSPITALAR in Sao Paulo runs $15,000 to $40,000 for a competitive presence. MEDICA in Dusseldorf costs $30,000 to $70,000 including booth, design, travel, and accommodation. Arab Health in Dubai adds another $25,000 to $50,000. Each event delivers three to five days of visibility at $300-$900+ per qualified lead, with no buyer engagement between events.

Can mid-size Brazilian manufacturers afford AI outbound?

Yes. AI outbound costs $150 to $300 per qualified lead, compared to $300-$900+ for trade fairs and $500-$1,200+ for field sales reps. A single MEDICA booth costs more than six months of AI-powered outreach across multiple markets. The cost per lead decreases over time as targeting improves, while trade fair costs stay flat or increase.

The Bottom Line

Brazil’s medical device sector crossed the $1 billion export mark and has not looked back. With 330+ manufacturers, ANVISA’s internationally aligned regulatory framework, and proven capability in high-complexity products like heart valves and orthopedic implants, the production side is strong. The gap is in market access. With 63.1% of exports concentrated in the Americas and Europe and Asia still underpenetrated, the manufacturers who build direct pipelines to hospital procurement teams and distributors in those regions will capture the growth that three trade fairs per year cannot deliver.

Read more about Brazilian pharmaceutical exporters and explore the broader picture of Brazil’s manufacturing exports. Or browse all our Brazil coverage.

If your company manufactures medical devices and needs a direct path to international buyers, let’s talk.